Copyright Reports & Markets. All rights reserved.

Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Proprotein Convertase Subtilisin/Kexin Type 9

      • 1.1 Definition of Proprotein Convertase Subtilisin/Kexin Type 9
      • 1.2 Proprotein Convertase Subtilisin/Kexin Type 9 Segment by Type
        • 1.2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 SX-PCK9
        • 1.2.3 O-304
        • 1.2.4 K-312
        • 1.2.5 BLSM-201
        • 1.2.6 DCRPCSK-9
        • 1.2.7 Others
      • 1.3 Proprotein Convertase Subtilisin/Kexin Type 9 Segment by Applications
        • 1.3.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Cardiovascular Disease
        • 1.3.3 Homozugous Familial Hyperchalesterolemia
        • 1.3.4 Liver Disease
        • 1.3.5 Metabolic Syndrome
        • 1.3.6 Others
      • 1.4 Global Proprotein Convertase Subtilisin/Kexin Type 9 Overall Market
        • 1.4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (2014-2025)
        • 1.4.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Production (2014-2025)
        • 1.4.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Status and Prospect (2014-2025)
        • 1.4.4 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Status and Prospect (2014-2025)
        • 1.4.5 China Proprotein Convertase Subtilisin/Kexin Type 9 Status and Prospect (2014-2025)
        • 1.4.6 Japan Proprotein Convertase Subtilisin/Kexin Type 9 Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Status and Prospect (2014-2025)
        • 1.4.8 India Proprotein Convertase Subtilisin/Kexin Type 9 Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Proprotein Convertase Subtilisin/Kexin Type 9
      • 2.3 Manufacturing Process Analysis of Proprotein Convertase Subtilisin/Kexin Type 9
      • 2.4 Industry Chain Structure of Proprotein Convertase Subtilisin/Kexin Type 9

      3 Development and Manufacturing Plants Analysis of Proprotein Convertase Subtilisin/Kexin Type 9

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Proprotein Convertase Subtilisin/Kexin Type 9
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Proprotein Convertase Subtilisin/Kexin Type 9 Production and Capacity Analysis
      • 4.2 Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Analysis
      • 4.3 Proprotein Convertase Subtilisin/Kexin Type 9 Price Analysis
      • 4.4 Market Concentration Degree

      5 Proprotein Convertase Subtilisin/Kexin Type 9 Regional Market Analysis

      • 5.1 Proprotein Convertase Subtilisin/Kexin Type 9 Production by Regions
        • 5.1.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Production by Regions
        • 5.1.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Regions
      • 5.2 Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Regions
      • 5.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Analysis
        • 5.3.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Production
        • 5.3.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Proprotein Convertase Subtilisin/Kexin Type 9 Import and Export
      • 5.4 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Analysis
        • 5.4.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Production
        • 5.4.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Import and Export
      • 5.5 China Proprotein Convertase Subtilisin/Kexin Type 9 Market Analysis
        • 5.5.1 China Proprotein Convertase Subtilisin/Kexin Type 9 Production
        • 5.5.2 China Proprotein Convertase Subtilisin/Kexin Type 9 Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Proprotein Convertase Subtilisin/Kexin Type 9 Import and Export
      • 5.6 Japan Proprotein Convertase Subtilisin/Kexin Type 9 Market Analysis
        • 5.6.1 Japan Proprotein Convertase Subtilisin/Kexin Type 9 Production
        • 5.6.2 Japan Proprotein Convertase Subtilisin/Kexin Type 9 Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Proprotein Convertase Subtilisin/Kexin Type 9 Import and Export
      • 5.7 Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Market Analysis
        • 5.7.1 Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Production
        • 5.7.2 Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Import and Export
      • 5.8 India Proprotein Convertase Subtilisin/Kexin Type 9 Market Analysis
        • 5.8.1 India Proprotein Convertase Subtilisin/Kexin Type 9 Production
        • 5.8.2 India Proprotein Convertase Subtilisin/Kexin Type 9 Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Proprotein Convertase Subtilisin/Kexin Type 9 Import and Export

      6 Proprotein Convertase Subtilisin/Kexin Type 9 Segment Market Analysis (by Type)

      • 6.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Production by Type
      • 6.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type
      • 6.3 Proprotein Convertase Subtilisin/Kexin Type 9 Price by Type

      7 Proprotein Convertase Subtilisin/Kexin Type 9 Segment Market Analysis (by Application)

      • 7.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Application
      • 7.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Market Share by Application (2014-2019)

      8 Proprotein Convertase Subtilisin/Kexin Type 9 Major Manufacturers Analysis

      • 8.1 AFFiRiS AG
        • 8.1.1 AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.1.2 AFFiRiS AG Product Introduction, Application and Specification
        • 8.1.3 AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Betagenon AB
        • 8.2.1 Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.2.2 Betagenon AB Product Introduction, Application and Specification
        • 8.2.3 Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Bioleaders Corp
        • 8.3.1 Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.3.2 Bioleaders Corp Product Introduction, Application and Specification
        • 8.3.3 Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 BioLingus AG
        • 8.4.1 BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.4.2 BioLingus AG Product Introduction, Application and Specification
        • 8.4.3 BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Catabasis Pharmaceuticals Inc
        • 8.5.1 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.5.2 Catabasis Pharmaceuticals Inc Product Introduction, Application and Specification
        • 8.5.3 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Dicerna Pharmaceuticals Inc
        • 8.6.1 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.6.2 Dicerna Pharmaceuticals Inc Product Introduction, Application and Specification
        • 8.6.3 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Eli Lilly and Co
        • 8.7.1 Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.7.2 Eli Lilly and Co Product Introduction, Application and Specification
        • 8.7.3 Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Ensemble Therapeutics Corp
        • 8.8.1 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.8.2 Ensemble Therapeutics Corp Product Introduction, Application and Specification
        • 8.8.3 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Kowa Co Ltd
        • 8.9.1 Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.9.2 Kowa Co Ltd Product Introduction, Application and Specification
        • 8.9.3 Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Novartis AG
        • 8.10.1 Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Production Sites and Area Served
        • 8.10.2 Novartis AG Product Introduction, Application and Specification
        • 8.10.3 Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Pfizer Inc
      • 8.12 Regeneron Pharmaceuticals Inc
      • 8.13 Serometrix LLC
      • 8.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
      • 8.15 The Medicines Company

      9 Development Trend of Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Market

      • 9.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Trend Analysis
        • 9.1.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Proprotein Convertase Subtilisin/Kexin Type 9 Regional Market Trend
        • 9.2.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Forecast 2019-2025
        • 9.2.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Forecast 2019-2025
        • 9.2.3 China Proprotein Convertase Subtilisin/Kexin Type 9 Forecast 2019-2025
        • 9.2.4 Japan Proprotein Convertase Subtilisin/Kexin Type 9 Forecast 2019-2025
        • 9.2.5 Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Forecast 2019-2025
        • 9.2.6 India Proprotein Convertase Subtilisin/Kexin Type 9 Forecast 2019-2025
      • 9.3 Proprotein Convertase Subtilisin/Kexin Type 9 Market Trend (Product Type)
      • 9.4 Proprotein Convertase Subtilisin/Kexin Type 9 Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Proprotein Convertase Subtilisin/Kexin Type 9 Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Proprotein Convertase Subtilisin/Kexin Type 9 market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Proprotein Convertase Subtilisin/Kexin Type 9 volume and value at global level, regional level and company level. From a global perspective, this report represents overall Proprotein Convertase Subtilisin/Kexin Type 9 market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Proprotein Convertase Subtilisin/Kexin Type 9 in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Proprotein Convertase Subtilisin/Kexin Type 9 manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        AFFiRiS AG
        Betagenon AB
        Bioleaders Corp
        BioLingus AG
        Catabasis Pharmaceuticals Inc
        Dicerna Pharmaceuticals Inc
        Eli Lilly and Co
        Ensemble Therapeutics Corp
        Kowa Co Ltd
        Novartis AG
        Pfizer Inc
        Regeneron Pharmaceuticals Inc
        Serometrix LLC
        Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
        The Medicines Company

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        SX-PCK9
        O-304
        K-312
        BLSM-201
        DCRPCSK-9
        Others

        Segment by Application
        Cardiovascular Disease
        Homozugous Familial Hyperchalesterolemia
        Liver Disease
        Metabolic Syndrome
        Others

        Buy now